10-Q/A: Bio Essence Corp. Reports Net Income of $133,939 for Q1 2024 After Restatement, Driven by Gains from Discontinued Operations

Bio Essence Corp. files an amended quarterly report (Form 10-Q/A) for the period ended March 31, 2024, reporting a net income of $133,939, primarily due to gains from the disposal of subsidiaries, while also restating prior period financials due to accounting errors.

Summary

• Bio Essence Corp. has filed an amended quarterly report on Form 10-Q/A for the period ended March 31, 2024.
• The company reported a net income of $133,939 for the three months ended March 31, 2024, compared to a net loss of $178,836 for the same period in 2023.
• This includes a gain of $377,752 from the disposal of a discontinued operation (BEH).
• The company sold its subsidiaries BEP and BEH for $300,000 and $400,000, respectively.
• The company restated its financial statements due to errors in prior accounting, including reclassification of receivables and adjustments to lease liabilities.
• The company's management expresses substantial doubt about its ability to continue as a going concern.
• The company plans to increase income through sales force improvements, incentive programs, and marketing activities.
• Management also intends to raise additional funds through private or public offerings, or by obtaining loans.
• The company had an accumulated deficit of $9,006,535 as of March 31, 2024.
• The company's current liabilities exceed current assets, resulting in a working capital deficit of $2,021,158.
• The company needs $1.2 million to continue its current business for the next 12 months.

Sentiment

Score: 4

Explanation: The sentiment is cautiously negative due to the going concern warning, restatement of financials, and need for additional funding, despite the reported net income driven by asset sales.

Positives

• The company achieved net income of $133,939 for the quarter, a significant improvement compared to the net loss in the same period last year.
• The company successfully disposed of two subsidiaries, generating gains of $67,451 and $377,752.
• The company is actively seeking additional funding to support its operations.
• The company is implementing strategies to increase income through sales and marketing efforts.

Negatives

• The company's management has expressed substantial doubt about its ability to continue as a going concern.
• The company has a significant accumulated deficit of $9,006,535.
• The company's current liabilities exceed current assets, resulting in a working capital deficit.
• The company's general and administrative expenses have increased significantly.
• The company restated its financial statements due to accounting errors, indicating potential weaknesses in internal controls.

Risks

• The company's ability to continue as a going concern is uncertain.
• The company may not be able to secure additional funding on acceptable terms or at all.
• The company's lack of liquidity could have a material adverse effect on its business viability.
• The company's reliance on loans from a major shareholder poses a risk if those loans are not available in the future.
• The company's restatement of financial statements indicates potential weaknesses in internal controls, which could lead to future errors or misstatements.

Future Outlook

The company plans to increase its income by strengthening its sales force, providing attractive sales incentive programs, and increasing marketing and promotion activities; management also intends to raise additional funds by way of a private or public offering, or by obtaining loans from banks or others.

Management Comments

• Management believes in the viability of its strategy to generate sufficient revenue and in its ability to raise additional funds on reasonable terms and conditions.
• Management needs $1.2 million cash to continue our current business for the next 12 months.

Industry Context

The health supplement industry is competitive, and Bio Essence faces challenges in accessing capital and maintaining liquidity; the company's shift to focus on prescription medicine development through McBE (though later dissolved) reflects an attempt to diversify and enter a higher-margin market.

Comparison to Industry Standards

• Given the limited information and the company's small size, it's difficult to make a direct comparison to industry standards.
• However, the company's negative working capital and accumulated deficit are concerning and suggest it is underperforming compared to healthier companies in the health supplement industry.
• Larger, more established companies in the health supplement industry, such as Herbalife or Amway, typically have stronger balance sheets and more diversified revenue streams.
• The company's reliance on related party loans is also a deviation from industry norms, where companies typically rely on traditional financing sources.

Related Party Transactions

• The Company had loans from one major shareholder (also the Company's senior officer) for $1,370,746 and $1,180,046, respectively, at March 31, 2024 and December 31, 2023.
• The Company had a loan from another major shareholder for $608,631 for settling the litigation at March 31, 2024 and December 31, 2023.
• On May 31, 2023, the Board of Directors of Bio Essence Corp. (the Company), approved a debt-to-equity conversion.

Stakeholder Impact

• Shareholders face significant risk due to the company's going concern warning and need for additional funding, which could dilute their ownership.
• Employees face uncertainty due to the company's financial instability.
• Customers may be concerned about the company's ability to continue providing products and services.
• Creditors face increased risk of non-payment due to the company's liquidity issues.

Next Steps

• The company needs to secure additional funding to address its liquidity issues.
• The company needs to improve its internal controls to prevent future accounting errors.
• The company needs to execute its plan to increase income through sales and marketing efforts.

Key Dates

Keywords

financial statements, discontinued operations, going concern, restatement, net income, subsidiaries, liquidity, funding, Bio Essence Corp